Successful in vivo propagation of factor IX-producing hepatocytes in mice: Potential for cell-based therapy in haemophilia B

Summary

Cell-based therapies using isolated hepatocytes have been proposed to be an attractive application in the treatment of haemophilia B due to the normal production of coagulation factor IX (FIX) in these particular cells. Current cell culture technologies have largely failed to provide adequate isolated hepatocytes, so the present studies were designed to examine a new approach to efficiently proliferate hepatocytes that can retain normal biological function, including the ability to synthesize coagulation factors like FIX. Canine or human primary hepatocytes were transplanted into urokinase-type plasminogen activatorsevere combined immunodeficiency (uPA/SCID) transgenic mice. Both donor hepatocytes from canines and humans were found to progressively proliferate in the recipient mouse livers as evidenced by a sharp increase in the circulating blood levels of species-specific albumin, which was correlated with the production and release of canine and human FIX antigen levels into the plasma. Histological examination confirmed that the transplanted canine and human hepatocytes were able to proliferate and occupy >80% of the host livers. In addition, the transplanted hepatocytes demonstrated strong cytoplasmic staining for human FIX, and the secreted coagulation factor IX was found to be haemostatically competent using specific procoagulant assays. In all, the results from the present study indicated that developments based on this technology could provide sufficient FIX-producing hepatocytes for cell-based therapy for haemophilia B.

Keywords

Haemophilia A/B - haemophilia therapy - coagulation factors - hepatology

^# Present address: PhoenixBio Co. Ltd, Hiroshima, Japan.

• References

• 1 Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet 2003; 361: 1801-1809.
• 2 Hsu TC, Nakaya SM, Thompson AR. Severe haemophilia B due to a 6 kb factor IX gene deletion including exon 4: non-homologous recombination associated with a shortened transcript from whole blood. Thromb Haemost 2007; 97: 176-180.
• 3 Nathwani AC, Davidoff AM, Tuddenham EG. Prospects for gene therapy of haemophilia. Haemophilia 2004; 10: 309-318.
• 4 Ehrhardt A, Kay MA. A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo. Blood 2002; 99: 3923-3930.
• 5 Herzog RW, Yang EY, Couto LB. et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 1999; 5: 56-63.
• 6 Kay MA, Rothenberg S, Landen CN. et al. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. Science 1993; 262: 117-119.
• 7 Miao CH, Thompson AR, Loeb K. et al. Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo. Mol Ther 2001; 3: 947-957.
• 8 Mount JD, Herzog RW, Tillson DM. et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood 2002; 99: 2670-2676.
• 9 Nathwani AC, Davidoff A, Hanawa H. et al. Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. Blood 2001; 97: 1258-1265.
• 10 Park F, Ohashi K, Kay MA. Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver. Blood 2000; 96: 1173-1176.
• 11 Xu L, Gao C, Sands MS. et al. Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B. Blood 2003; 101: 3924-3932.
• 12 Yant SR, Meuse L, Chiu W. et al. Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat Genet 2000; 25: 35-41.
• 13 Manno CS, Chew AJ, Hutchison S. et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003; 101: 2963-2972.
• 14 Manno CS, Pierce GF, Arruda VR. et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342-347.
• 15 Bontempo FA, Lewis JH, Gorenc TJ. et al. Liver transplantation in hemophilia A. Blood 1987; 69: 1721-1724.
• 16 Ko S, Tanaka I, Kanehiro H. et al. Preclinical experiment of auxiliary partial orthotopic liver transplantation as a curative treatment for hemophilia. Liver Transpl 2005; 11: 579-584.
• 17 Merion RM, Delius RE, Campbell DA. Jr. et al. Orthotopic liver transplantation totally corrects factor IX deficiency in hemophilia B. Surgery 1988; 104: 929-931.
• 18 Boost KA, Auth MK, Woitaschek D. et al. Long-term production of major coagulation factors and inhibitors by primary human hepatocytes in vitro: perspectives for clinical application. Liver Int 2007; 27: 832-844.
• 19 Greenberg D, Miao CH, Ho WT. et al. Liver-specific expression of the human factor VII gene. Proc Natl Acad Sci USA 1995; 92: 12347-12351.
• 20 Hjortoe G, Sorensen BB, Petersen LC. et al. Factor VIIa binding and internalization in hepatocytes. J Thromb Haemost 2005; 3: 2264-2273.
• 21 Hollestelle MJ, Thinnes T, Crain K. et al. Tissue distribution of factor VIII gene expression in vivo–a closer look. Thromb Haemost 2001; 86: 855-861.
• 22 Kelly DA, Summerfield JA, Tuddenham EG. Localization of factor VIIIC: antigen in guinea-pig tissues and isolated liver cell fractions. Br J Haematol 1984; 56: 535-543.
• 23 Rodriguez-Inigo E, Bartolome J, Quiroga JA. et al. Expression of factor VII in the liver of patients with liver disease: correlations with the disease severity and impairment in the hemostasis. Blood Coagul Fibrinolysis 2001; 12: 193-199.
• 24 Wion KL, Kelly D, Summerfield JA. et al. Distribution of factor VIII mRNA and antigen in human liver and other tissues. Nature 1985; 317: 726-729.
• 25 Ohashi K, Kay MA, Kuge H. et al. Heterotopically transplanted hepatocyte survival depends on extracellular matrix components. Transplant Proc 2005; 37: 4587-4588.
• 26 Ohashi K, Kay MA, Yokoyama T. et al. Stability and repeat regeneration potential of the engineered liver tissues under the kidney capsule in mice. Cell Transplant 2005; 14: 621-627.
• 27 Ohashi K, Marion PL, Nakai H. et al. Sustained survival of human hepatocytes in mice: A model for in vivo infection with human hepatitis B and hepatitis delta viruses. Nat Med 2000; 6: 327-331.
• 28 Ohashi K, Waugh JM, Dake MD. et al. Liver tissue engineering at extrahepatic sites in mice as a potential new therapy for genetic liver diseases. Hepatology 2005; 41: 132-140.
• 29 Ohashi K, Yokoyama T, Yamato M. et al. Engineering functional two- and three-dimensional liver systems in vivo using hepatic tissue sheets. Nat Med 2007; 13: 880-885.
• 30 Yokoyama T, Ohashi K, Kuge H. et al. In vivo engineering of metabolically active hepatic tissues in a neovascularized subcutaneous cavity. Am J Transplant 2006; 6: 50-59.
• 31 Dhawan A, Mitry RR, Hughes RD. et al. Hepatocyte transplantation for inherited factor VII deficiency. Transplantation 2004; 78: 1812-1814.
• 32 Ostrowska A, Bode DC, Pruss J. et al. Investigation of functional and morphological integrity of freshly isolated and cryopreserved human hepatocytes. Cell Tissue Bank 2000; 1: 55-68.
• 33 Ohashi K, Park F, Kay MA. Hepatocyte transplantation: clinical and experimental application. J Mol Med 2001; 79: 617-630.
• 34 Kobayashi N, Fujiwara T, Westerman KA. et al. Prevention of acute liver failure in rats with reversibly immortalized human hepatocytes. Science 2000; 287: 1258-1262.
• 35 Tateno C, Yoshizane Y, Saito N. et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 2004; 165: 901-912.
• 36 Hamatani K, Matsuda Y, Araki R. et al. Cloning and chromosomal mapping of the mouse DNA-dependent protein kinase gene. Immunogenetics 1996; 45: 1-5.
• 37 Emoto K, Tateno C, Hino H. et al. Efficient in vivo xenogeneic retroviral vector-mediated gene transduction into human hepatocytes. Hum Gene Ther 2005; 16: 1168-1174.
• 38 Yoshitsugu H, Nishimura M, Tateno C. et al. Evaluation of human CYP1A2 and CYP3A4 mRNA expression in hepatocytes from chimeric mice with humanized liver. Drug Metab Pharmacokinet 2006; 21: 465-474.
• 39 Greene AK, Puder M. Partial hepatectomy in the mouse: technique and perioperative management. J Invest Surg 2003; 16: 99-102.
• 40 Ito Y, Hayashi H, Taira M. et al. Depression of liver-specific gene expression in regenerating rat liver: a putative cause for liver dysfunction after hepatectomy. J Surg Res 1991; 51: 143-147.
• 41 Kurumiya Y, Nozawa K, Sakaguchi K. et al. Differential suppression of liver-specific genes in regenerating rat liver induced by extended hepatectomy. J Hepatol 2000; 32: 636-644.
• 42 Rawle FE, Lillicrap D. Preclinical animal models for hemophilia gene therapy: predictive value and limitations. Semin Thromb Hemost 2004; 30: 205-213.
• 43 Fisher RA, Strom SC. Human hepatocyte transplantation: worldwide results. Transplantation 2006; 82: 441-449.
• 44 Huth-Kuhne A, Rott H, Zimmermann R. et al. Recombinant factor VIIa for long-term replacement therapy in patients with congenital factor VII deficiency. Thromb Haemost 2007; 98: 912-915.
• 45 Rosenthal C, Volk T, Spies C. et al. Successful coronary artery bypass graft surgery in severe congenital factor VII deficiency: perioperative treatment with factor VII concentrate. Thromb Haemost 2007; 98: 900-902.
• 46 Arruda VR, Hagstrom JN, Deitch J. et al. Post-translational modifications of recombinant myotube-synthesized human factor IX. Blood 2001; 97: 130-138.
• 47 Masumoto N, Tateno C, Tachibana A. et al. GH enhances proliferation of human hepatocytes grafted into immunodeficient mice with damaged liver. J Endocrinol 2007; 194: 529-537.
• 48 Walldorf J, Aurich H, Cai H. et al. Expanding hepatocytes in vitro before cell transplantation: donor agedependent proliferative capacity of cultured human hepatocytes. Scand J Gastroenterol 2004; 39: 584-593.
• 49 Azuma H, Paulk N, Ranade A. et al. Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol 2007; 25: 903-910.
• 50 Slehria S, Rajvanshi P, Ito Y. et al. Hepatic sinusoidal vasodilators improve transplanted cell engraftment and ameliorate microcirculatory perturbations in the liver. Hepatology 2002; 35: 1320-1328.